Teva Pharmaceutical Industries Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TEVA New York 2830 www.tevapharm.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Teva Pharmaceutical Industries Limited

Hoka Expected to Drive First Quarter Earnings Results for Deckers, Analysts Say - Jul 21st, 2026 3:09 pm
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised - Jul 15th, 2026 8:50 am
Teva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progress - Jul 13th, 2026 10:31 pm
Deckers Brands Announces Conference Call to Review First Quarter Fiscal 2027 Earnings Results - Jul 13th, 2026 2:05 pm
Teva (TEVA) Stock Looks Discounted On Cash Flow Yet Fair On Earnings - Jul 13th, 2026 9:11 am
Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release? - Jul 13th, 2026 8:43 am
Teva (TEVA) Reports Promising Vitiligo Trial Results And Moves Anti IL 15 Drug Forward - Jul 13th, 2026 6:07 am
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study - Jul 12th, 2026 4:02 pm
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk - Jul 12th, 2026 3:02 pm
Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar - Jul 10th, 2026 4:31 am
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - Jul 9th, 2026 10:32 am
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength? - Jul 9th, 2026 7:25 am
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis - Jul 9th, 2026 6:45 am
Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in Canada - Jul 9th, 2026 6:05 am
JPMorgan resets LLY stock target on drug demand - Jul 8th, 2026 11:07 pm
Teva draws up mid-stage study plans for vitiligo asset on Phase Ib success - Jul 8th, 2026 4:57 am
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results - Jul 7th, 2026 5:00 am
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - Jul 6th, 2026 11:29 am
Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update? - Jun 30th, 2026 7:08 am
Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results? - Jun 24th, 2026 7:27 am